Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Lunger John

2. Date of Event Requiring Statement (Month/Day/Year)
08/01/2019

3. Issuer Name and Ticker or Trading Symbol
Adaptimmune Therapeutics PLC [ADAP]

(Last)

(First)

(Middle)

216 WOODSTOCK ROAD

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Chief Patient Supply Officer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

VILLONOVA, PA 19085

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares with a nominal value of GBP0.001 per share ⁽¹⁾	28,806	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option to purchase Ordinary Shares	⁽²⁾	04/03/2027	Ordinary Shares	250,032	$ 0.92 ⁽³⁾	D
Option to purchase Ordinary Shares	⁽⁴⁾	07/07/2027	Ordinary Shares	300,000	$ 0.81 ⁽⁵⁾	D
Option to purchase Ordinary Shares	⁽⁶⁾	01/12/2028	Ordinary Shares	100,800	$ 1.3 ⁽⁷⁾	D
Option to purchase Ordinary Shares	⁽⁸⁾	⁽⁹⁾	Ordinary Shares	50,850	$ 0.0014 ⁽¹⁰⁾	D
Option to purchase Ordinary Shares	⁽¹¹⁾	07/02/2028	Ordinary Shares	181,872	$ 1.98 ⁽¹²⁾	D
Option to purchase Ordinary Shares	⁽¹³⁾	⁽¹⁴⁾	Ordinary Shares	91,386	$ 0.0013 ⁽¹⁵⁾	D
Option to purchase Ordinary Shares	⁽¹⁶⁾	01/04/2029	Ordinary Shares	100,800	$ 0.89 ⁽¹⁷⁾	D
Option to purchase Ordinary Shares	⁽¹⁸⁾	⁽¹⁹⁾	Ordinary Shares	67,800	$ 0.0013 ⁽²⁰⁾	D

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Lunger John 216 WOODSTOCK ROAD VILLONOVA, PA 19085			Chief Patient Supply Officer

Signatures

/s/ John Lunger		08/05/2019
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Represented by 4,801 American Depositary Shares ("ADS") held by Mr. Lunger. Mr. Lunger holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer.
(2)	Exercisable as to 62,508 Ordinary Shares on April 3, 2018 and will be exercisable as to the remainder in monthly installments of 5,209 Ordinary Shares on the third of each month from May 3, 2018 through April 3, 2021.
(3)	The exercise price was converted from GBP0.74 based on an exchange rate of U.S.$1.2493 to GBP1.00. The actual exercise price will be the pounds sterling amount.
(4)	Exercisable as to 75,000 Ordinary Shares on July 7, 2018 and will be exercisable as to the remainder in monthly installments of 6,250 Ordinary Shares on the seventh of each month from August 7, 2018 through July 7, 2021.
(5)	The exercise price was converted from GBP0.62 based on an exchange rate of U.S.$1.2949 to GBP1.00. The actual exercise price will be the pounds sterling amount.
(6)	Exercisable as to 25,200 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 2,100 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022.
(7)	The exercise price was converted from GBP0.96 based on an exchange rate of U.S.$1.3542 to GBP1.00. The actual exercise price will be the pounds sterling amount.
(8)	Exercisable as to 16,950 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 16,950 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022.
(9)	The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.
(10)	The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.3542 to GBP1.00. The actual exercise price will be the pounds sterling amount.
(11)	Exercisable as to 45,468 Ordinary Shares on July 2, 2019 and will be exercisable as to the remainder in monthly installments of 3,789 Ordinary Shares on the second of each month from August 2, 2019 through July 2, 2022.
(12)	The exercise price was converted from GBP1.50 based on an exchange rate of U.S.$1.3196 to GBP1.00. The actual exercise price will be the pounds sterling amount.
(13)	Exercisable as to 30,462 Ordinary Shares on July 2, 2019 and will be exercisable as to the remainder in annual installments of 30,462 Ordinary Shares on the second of each July from July 2, 2020 through July 2, 2022.
(14)	The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.
(15)	The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.3196 to GBP1.00. The actual exercise price will be the pounds sterling amount.
(16)	Exercisable as to 25,200 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 2,100 Ordinary Shares on the fourth of each month from February 4, 2020 through January 4, 2023.
(17)	The exercise price was converted from GBP0.70. based on an exchange rate of U.S.$1.2633 to GBP1.00. The actual exercise price will be the pounds sterling amount.
(18)	Exercisable as to 16,950 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 16,950 Ordinary Shares on the fourth of each January from January 4, 2021 through January 4, 2023.
(19)	The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.
(20)	The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.2633 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.